Further studies on the  -adrenoceptor blocking action of  -adrenoceptor blocking agents.
D000317:Adrenergic alpha-Antagonists / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D000319:Adrenergic beta-Antagonists / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D000818:Animals; D002078:Butoxamine / Q000494:pharmacology; D002395:Catecholamines / Q000494:pharmacology; D003042:Cocaine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004837:Epinephrine / Q000494:pharmacology; D066298:In Vitro Techniques; D007545:Isoproterenol / Q000494:pharmacology; D002040:Levobunolol / Q000494:pharmacology; D008297:Male; D008729:Methoxamine / Q000494:pharmacology; D009474:Neurons / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism / Q000494:pharmacology; D010643:Phenoxybenzamine / Q000494:pharmacology; D010656:Phenylephrine / Q000494:pharmacology; D011189:Potassium Chloride / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D051381:Rats; D012669:Seminal Vesicles / Q000187:drug effects; D014439:Tyramine / Q000494:pharmacology
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D002395:Catecholamines; D002078:Butoxamine; D010643:Phenoxybenzamine; D010656:Phenylephrine; D011189:Potassium Chloride; D011433:Propranolol; D002040:Levobunolol; D008729:Methoxamine; D003042:Cocaine; D007545:Isoproterenol; D009638:Norepinephrine; D014439:Tyramine; D004837:Epinephrine